Showing results (1-10 of 226) with videos related to

Sort By:
Pageof 23
Current Opinion in Oncology|September 1, 2007
Maintenance therapy for low-grade lymphomas: has the time come?Guillaume Cartron, Philippe Solal-Céligny
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 7, 2011
Interindividual variability of response to rituximab: from biological origins to individualized therapiesGuillaume Cartron, Ralf Ulrich Trappe, Philippe Solal-Céligny, et al.
Seminars in Oncology|June 1, 2002
Increasing treatment options in indolent non-Hodgkin's lymphomaPhilippe Solal-Céligny
Leukemia Research|June 6, 2006
Safety of rituximab maintenance therapy in follicular lymphomasPhilippe Solal-Céligny
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 10, 2013
Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN studyGilles A Salles, Franck Morschhauser, Philippe Solal-Céligny, et al.
British Journal of Haematology|December 13, 2017
A retrospective study on the management of patients with rituximab refractory follicular lymphomaPhilippe Solal-Céligny, Pierre Leconte, Aurélie Bardet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 10, 2013
Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN studyFranck Andre Morschhauser, Guillaume Cartron, Catherine Thieblemont, et al.
Anti-Cancer Drugs|April 25, 2003
Rituximab therapy for indolent non-Hodgkin's lymphomaAnton Hagenbeek, Myron S Czuczman, Michele Ghielmini, et al.
Haematologica|January 5, 2022
Time for an individualized approach to first-line management of follicular lymphomaGuillaume Cartron, Judith Trotman
Pageof 23